Gene-Disorder Association · Article
First reported
1996
Supporting publications
44
Manually curatedApproved treatment annotated
Association Review
In brief
The association between CCND1 (Cyclin D1) and Melanoma is reported, with clinical genetic testing available.
Sources
1
Clinical variants
0
Symptoms
2
Compounds
1
Trials
40of 87 via CCND1 compounds
Publications
44
01
At a glance
Association overview
A cited synthesis of the gene–disorder association, with a clinical-actionability summary where the evidence supports one.
Request access
02
Provenance
Evidence and sources
1 source
Every contributing database and publication behind this association, with evidence type, strength, accessions and deep links.
Request access
2 source summaries
A gene summary alongside the source descriptions it was distilled from.
Request access
7 database identifiers
The disorder’s summary, prevalence, aliases and cross-reference identifiers (OMIM, Orphanet, MONDO, ICD-10, MedGen).
Request access
05
Population genetics
GWAS signals
2 GWAS phenotypes
Gene-associated GWAS phenotypes matching the disorder, with best SNP, score, risk-allele frequency and effect size.
Request access
06
Mechanism overlap
Shared mechanisms
1 shared pathway
Biological pathways and phenotype concepts shared by the gene and the disorder, with supporting publications.
Request access
07
Interventions
Therapeutics
1 compound or drug
Gene-targeting drugs and associated compounds, with class, approval status, mechanism, indications and trials.
Request access
08
Human studies
Clinical trials
87 clinical trials
Clinical trials reached through the pair’s compounds, keeping disorder-targeting trials separate from other indications.
Request access
44 publications
Publications linking the gene and the disorder, with title, authors, journal, year and citation metrics.
Request access
10
Provenance
References & sources
19 references
Every source and publication cited across this dossier, as one numbered reference list.
Request access